Shares of biotechnology company Alnylam Pharmaceuticals (Nasdaq: ALNY) have fallen by approximately 40% year-to-date, but Wall Street analysts remain largely optimistic about its prospects. According to an S&P Global survey of 29 analysts in September, 22 gave a "buy" or "strong buy" rating, while the remaining 7 recommended "hold." The average 12-month price target provided by analysts suggests a potential upside of about 50% for the stock. Reasons for analysts' optimism include: Alnylam's second-quarter revenue grew by 72% year-over-year, with an anticipated 75% growth for the full year 2026; Pfizer's competing drug Vyndaqel/Vyndamax will not face generic competition in the U.S. market until mid-2031, providing room for growth for Alnylam's Amvuttra; furthermore, disappointing late-stage clinical results for AstraZeneca's similar experimental therapy Wainua may benefit Alnylam's nucresiran. Alnylam expects nucresiran to be used for the treatment of ATTR-PN and ATTR-CM in 2028 and 2030, respectively.